Premium
Anagrelide‐Induced Cardiomyopathy
Author(s) -
James Christopher W.
Publication year - 2000
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.20.15.1224.34591
Subject(s) - medicine , heart failure , anagrelide , cardiotoxicity , cardiology , cardiomyopathy , inotrope , palpitations , dexrazoxane , polycythemia vera , chemotherapy , anthracycline , cancer , essential thrombocythemia , breast cancer
Anagrelide, a selective thrombocytopenic agent, is administered to treat a variety of hematologic disorders. Despite limited clinical experience with this drug, serious cardiovascular events, including congestive heart failure, have been reported. The proposed mechanism of cardiotoxicity is attributed to inhibition of phosphodiesterase, resulting in positive inotropic activity and vasodilation. A 48‐year‐old woman with polycythemia vera developed cardiotoxicity manifested by congestive heart failure and palpitations. It was suspected to be temporally related to titrating dosages of anagrelide.